Global Pediatric Healthcare Industry By Drug Class (Antibiotics, Analgesics, And Antidepressants), By Disease (Allergy, Respiratory, Cancer, and Cardiovascular), and By Services (Child Psychiatry Services, Gastrointestinal Services, and Pediatric Cancer Services) - Market Forecast and Size Analysis 2019-2025.

  • Product Code:
    RP-ID-10078919
  • Published Date:
    28 Sep 2020
  • Region:
    Global
  • Pages:
    111
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-27

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

Global Pediatric Healthcare Industry was valued at USD 123.7 Billion in the year 2017. Global Pediatric Healthcare Industry is further estimated to grow at a CAGR of 3.8% from 2019 to reach USD 166.96 Billion by the year 2025. The North America region holds the highest Industry share in 2017 and the Asia Pacific is considered as the fastest growing Industry in the forecasted period. At a country level, US, China and the U.S. are projected to grow strongly in the coming years due to increasing density of population.

Major market players in Pediatric Healthcare Industry are Pfizer Inc., GlaxoSmithKline plc., Merck & Co. Inc, AstraZeneca plc., Boehringer Ingelheim GmbH, Gilead Sciences Inc., Sanofi S.A.,
Pediapharm Inc., Novartis AG, Eisai Co. Ltd., Mylan N.V., and brief overview of 9 companies is also provided in the report. Rising research and development expenses are catering to changing demand of end users. Similarly, growth strategies such as acquisition, merger, and expansion of the distribution network were few techniques adopted by most of Tier 1 and Tier 2 manufacturers in recent years.

SWOT Analysis of Pediatric Healthcare Industry:
Strength:
Changes in lifestyle
Rising awareness towards pediatric disorders
Weakness:
High cost
Opportunities:
Advancement in technology
Threats:
Inadequate regulatory funding

The Drug Class segment is divided as Antibiotics, Analgesics, Antidepressants, Antidiarrheal, Antifungal, Anti-histamines, Anti-hypertensives, Anti-metabolites, Anti-neoplastic Antibiotics, Antipyschotics and Others in which the anti-biotics segment contributes to the highest share in the Industry. Antibiotics are extensively utilized, particularly for pediatric patients, due to their efficacy in treating bacterial infections.

Pediatric Healthcare Industry Segmentation:
By Drug Class
• Antibiotics
• Analgesics
• Antidepressants
• Antidiarrheal
• Antifungal
• Anti-histamines
• Anti-hypertensives
• Anti-metabolites
• Anti-neoplastic Antibiotics
• Antipyschotics
• Others

By Disorder/Disease
• Allergy and Respiratory
• Cancer
• Cardiovascular
• Central Nervous System
• Gastrointestinal
• Hormonal Imbalance
• Infections
• Others

By Services
• Child Psychiatry Services
• Gastrointestinal Services
• Pediatric Cancer Services
• Pediatric Diabetes Services
• Pediatric Heart Services
• Others

By Region
North America
• USA
• Canada
Europe
• Germany
• U.K.
• France
• Italy
• Rest of Europe
APAC
• China
• India
• Japan
• Rest of Asia-Pacific
RoW
• Latin America
• Middle East & Africa

1. Introduction
1.1 Industry Vision
1.1.1 Industry Definition
1.1.2 Industry Scope
1.2 Limitations
1.3 Stakeholders
2. Research Methodology
2.1. Research Process
2.1.1. Secondary Research
2.1.1.1. Key Data from Secondary Research
2.1.2. Primary Research
2.1.2.1. Key Data from Primary Research
2.1.2.2. Breakdowns of Primary Interviews
2.2. Industry Size Estimation
2.2.1. Bottom-Up Approach
2.2.2. Top-Down Approach
2.2.3. Annual Revenue Process
2.3. Data Triangulation
2.4. Research Assumptions
2.4.1. Assumption
3. Executive Summary
4. Industry Overview
4.1. Introduction
4.2. Strength
4.3. Weakness
4.4. Opportunities
4.5. Threats
4.6. Regulations
4.7. Supply Chain/Value Chain Analysis
4.10. Patent & Standards
5. Industry Trends
5.1. Introduction
5.2. Porter’s Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Buyers
5.2.4. Bargaining Power of Suppliers
5.2.5. Intensity of Competitive Rivalry
6. Pediatric Healthcare Industry, By Disorder/Disease
6.1 Allergy and Respiratory
6.2 Cancer
6.3 Cardiovascular
6.4 Central Nervous System
6.5 Gastrointestinal
6.6 Hormonal Imbalance
6.7 Infections
6.8 Others
7. Pediatric Healthcare Industry, By Drug Class
7.1 Antibiotics
7.2 Analgesics
7.3 Antidepressants
7.4 Antidiarrheal
7.5 Antifungal
7.6 Anti-histamines
7.7 Anti-hypertensives
7.8 Anti-metabolites
7.9 Anti-neoplastic Antibiotics
7.10 Antipyschotics
7.11 Others
8. Pediatric Healthcare Industry, By Services
8.1 Child Psychiatry Services
8.2 Gastrointestinal Services
8.3 Pediatric Cancer Services
8.4 Pediatric Diabetes Services
8.5 Pediatric Heart Services
8.6 Others
9 Geographical Analysis
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. RoE
9.4. Asia Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. RoAPAC
9.5. RoW
9.5.1. Latin America
9.5.1.1. Brazil
9.5.1.2. Argentina
9.5.1.3. Rest of Latin America
9.5.2. Middle East and Africa
10. Company Profiles
10.1 Pfizer Inc.,
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Overview
10.1.4 Current Development
10.2 GlaxoSmithKline Plc.
10.3 Merck & Co., Inc,
10.4 AstraZeneca Plc.
10.5 Boehringer Ingelheim GmbH,
10.6 Gilead Sciences, Inc.,
10.7 Sanofi S.A.,
10.8 Pediapharm, Inc.
10.9 Novartis AG, Eisai Co., Ltd.,
10.10 Mylan N.V.
10. Competitive Analysis
10.1. Introduction
10.2. Industry Positioning of Key Players
10.3 Competitive Strategies Adopted by Leading Players
10.3.1. Investments & Expansions
10.3.2. New Product Launches
10.3.3. Mergers & Acquisitions
10.3.4. Agreements, Joint Ventures, and Partnerships
11. Appendix
11.1. Questionnaire
11.2. Available Customizations
11.3. Upcoming Events (Trade Fair, Exhibitions, Conferences)

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports